Clinical Trial Detail
| NCT ID | NCT02624570 |
| Title | Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy. |
| Recruitment | No longer available |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult |
CKB BOOST